We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Kidney Precision Medicine Project (KPMP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04334707
Recruitment Status : Recruiting
First Posted : April 6, 2020
Last Update Posted : May 19, 2022
Sponsor:
Collaborators:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
University of Michigan
Icahn School of Medicine at Mount Sinai
Brigham and Women's Hospital
Broad Institute
The Cleveland Clinic
Columbia University
European Molecular Biology Laboratory
Indiana University
Johns Hopkins University
Joslin Diabetes Center
Pacific Northwest National Laboratory
Princeton University
Stanford University
Ohio State University
University of California, San Diego
University of California, San Francisco
University of Pittsburgh
The University of Texas Health Science Center at San Antonio
University of Texas
Washington University School of Medicine
Yale University
Information provided by (Responsible Party):
Jonathan Himmelfarb, University of Washington

Tracking Information
First Submitted Date March 23, 2020
First Posted Date April 6, 2020
Last Update Posted Date May 19, 2022
Actual Study Start Date September 1, 2019
Estimated Primary Completion Date June 30, 2027   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: April 1, 2020)
  • Biopsy-related outcomes [ Time Frame: Immediately after the procedure for up to 6 months ]
    Biopsy-related complications will be collected by KPMP study staff using standardized case report forms. Clinical utility of the biopsy results will be assessed using standardized surveys of clinical providers, and participant-reported outcomes will be assessed using standardized questionnaires. Biopsy-related outcomes data will be collected around the time of the biopsy and within the six months following procurement of the kidney biopsy.
  • Kidney disease progression outcomes [ Time Frame: Through study completion (up to 10 years, depending on enrollment date of participant) ]
    Longitudinal change in estimated glomerular filtration rate (eGFR):
    • Primary composite longitudinal outcome, defined by any of the following:
    • ESRD, defined as initiation of maintenance dialysis or kidney transplantation
    • Sustained decline in eGFR by 40% or more from baseline
    • Individual components of the primary composite outcome
    • Slope of eGFR change (from baseline to the latest value)
  • Kidney disease progression outcomes [ Time Frame: Through study completion (up to 10 years, depending on enrollment date of participant) ]
    Longitudinal change in urine albumin excretion defined by the following: -Slope of change in urine albumin-creatinine ratio
  • Kidney disease progression outcomes [ Time Frame: Through study completion (up to 10 years, depending on enrollment date of participant) ]
    Longitudinal change in urine albumin excretion defined by the following: -Change of Kidney Disease Improving Global Outcomes (KDIGO) albuminuria stage
Original Primary Outcome Measures Same as current
Change History
Current Secondary Outcome Measures Not Provided
Original Secondary Outcome Measures Not Provided
Current Other Pre-specified Outcome Measures
 (submitted: April 1, 2020)
  • Number of Participants with Additional Outcome Measures [ Time Frame: Through study completion (up to 10 years, depending on enrollment date of participant) ]
    • All-cause mortality, defined by death from any cause and validated through linkages with the National Death Index (NDI)
    • Cardiovascular events, including heart failure, myocardial infarction, cerebrovascular event, transient ischemic attack, thromboembolic event, arrhythmia, and cardiac arrest
    • New AKI events after KPMP enrollment
    • Hospital admissions and discharge diagnoses after KPMP enrollment
  • Number of Participants with Outcomes Specific to AKI [ Time Frame: Through study completion (up to 10 years, depending on enrollment date of participant) ]
    • Duration of AKI: number of days with elevated serum creatinine above baseline
    • Recovery of AKI: return of serum creatinine to greater than 125% of baseline by 3 months post-biopsy
    • ICU admissions: admissions to any intensive care unit during hospitalization
    • Need for dialysis: initiation and duration of any dialysis modality (CRRT, HD, or PD)
    • Length of hospital stay: number of days during initial AKE episode
Original Other Pre-specified Outcome Measures Same as current
 
Descriptive Information
Brief Title Kidney Precision Medicine Project
Official Title Kidney Precision Medicine Project
Brief Summary

Acute kidney injury (AKI) and chronic kidney disease (CKD) impose a significant global health burden. Yet, no effective therapies currently exist for AKI, and only a few are available for CKD.

Despite significant effort from industry and academia, development of pharmacologic therapies for AKI and CKD has been hampered by:

Non-predictive animal models The inability to identify and prioritize human targets The limited availability of human kidney biopsy tissue A poor understanding of AKI and CKD heterogeneity Historically, AKI and CKD have been described as single, uniform diseases. However, growing consensus suggests that different disease pathways lead to different subgroups of AKI and CKD (AKIs and CKDs).

Access to human kidney biopsy tissue is a critical first step to define disease heterogeneity and determine the precise molecular pathways that will facilitate identification of specific drug targets and ultimately enable individualized care for people with AKI and CKD.

A number of research centers across the United States are collaborating to bring state-of-the-art technologies together to:

  • Ethically obtain and evaluate kidney biopsies from participants with AKI or CKD
  • Define disease subgroups
  • Create a kidney tissue atlas
  • Identify critical cells, pathways, and targets for novel therapies

The KPMP is made up of three distinct, but highly interactive, activity groups:

  • Recruitment Sites: The recruitment sites (RS) are responsible for recruiting participants with AKI or CKD into the longitudinal study and performing the kidney biopsy.
  • Tissue Interrogation Sites: The tissue interrogation sites (TIS) are responsible for developing and using innovative technologies to analyze the biopsy tissue.
  • Central Hub: The central hub is responsible for aggregating, analyzing, and visualizing the generated data and providing scientific, infrastructure, and administrative support for the KPMP consortium.
Detailed Description

The Kidney Precision Medicine Project (KPMP) is a prospective cohort study, whose goal is to use deep molecular phenotypes of kidney biopsies, along with longitudinally collected clinical phenotypic data, in order to develop new disease ontologies, classification systems, and treatments for acute kidney injury (AKI) and chronic kidney disease (CKD). Since its inception, the KPMP has sought out and included substantive patient-representative feedback regarding disease experience, lack of innovation in new kidney disease therapies and patient tolerance for risk levels in balance with potential benefits both to the individual and society.

The KPMP Has publicly and operationally committed itself to always put participants and their best interests first and this foundational principle informs and undergirds every facet of the study. Both AKI and CKD are conditions that impose a significant global health burden. Yet, no effective therapies currently exist for AKI, and only a few are available for CKD. The network will utilize state-of-the-art methods to perform molecular interrogation of the tissue and to link the molecular data to kidney structure and clinical information in the form of a kidney tissue atlas.

Molecular and imaging data derived from kidney tissue will be integrated with clinico-pathologic and genetic information, as well as other data derived from analyses of fluid biospecimens, including peripheral blood, urine, and stool. Using advanced analytics to integrate the data, KPMP will aim to define kidney disease subgroups in molecular terms by identifying critical cells, pathways and targets for novel therapies.

Patients with AKI or CKD will be recruited from clinical care encounters (e.g., clinic visits for CKD patients, hospitalization or emergency room visits for AKI patients) and from electronic resources (e.g., existing registries, electronic health records). All study procedures are designed to optimize participant safety and will be ethically conducted, ensuring subjects fully understand the scope of the study and any possible risks.

For each participant, kidney tissue will be obtained for molecular phenotyping and clinical diagnosis. The diagnostic interpretation will be returned to the participant's primary caregiver to inform clinical care, but no treatment interventions will be prescribed by the KPMP. In addition to kidney biopsy, the study will involve collection of baseline (time of biopsy) and longitudinal biospecimens (including urine, plasma, serum, DNA and stool) and demographic, clinical, and laboratory data. Participants will be followed through scheduled in-person and remote (telephone) study visits, as well as through periodic review of electronic health records.

Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Retention:   Samples With DNA
Description:
Kidney (renal) tissue will be obtained from all study participants at study entry Blood and urine will be collected longitudinally, including DNA One-time stool sample
Sampling Method Non-Probability Sample
Study Population

The KPMP will focus on participant populations that account for large proportions of the public health burden of acute and chronic kidney diseases as evidenced by research and federal data.

For CKD, high priority populations include CKD in the setting of diabetes (diabetic kidney disease, DKD) and hypertension-associated CKD (H-CKD). A special population of people with long-standing type 1 diabetes (more than 25 years) who remain free of clinically-evident DKD will also be included.

For AKI, the focus will be on acute intrinsic non-glomerular disease, primarily on acute tubular necrosis (ATN). KPMP will also include a special population of patients at risk for AKI or with early AKI captured by an open (surgical) kidney biopsy performed at the time of clinically indicated laparotomy. The rationale for including this special AKI population is that AKI often occurs early in the clinical course of conditions like sepsis, major surgery and trauma.

Condition
  • Acute Kidney Failure
  • Acute Kidney Insufficiency
  • Acute Renal Failure
  • Acute Renal Injury
  • Acute Renal Insufficiency
  • Kidney Failure, Acute
  • Kidney Insufficiency, Acute
  • Renal Failure, Acute
  • Renal Insufficiency, Acute
  • Chronic Kidney Diseases
  • Chronic Kidney Insufficiency
  • Chronic Renal Diseases
  • Chronic Renal Insufficiency
  • Kidney Insufficiency, Chronic
Intervention Procedure: Kidney Biopsy
A kidney biopsy is a procedure that involves taking a small piece of kidney tissue for examination with a microscope. A licensed health care provider will perform a kidney biopsy.
Other Names:
  • Renal Biopsy
  • Laparotomy
Study Groups/Cohorts
  • Acute Kidney Injury Cohort
    The focus will be on acute intrinsic non-glomerular disease, primarily on acute tubular necrosis (ATN). KPMP will also include a special population of patients at risk for AKI or with early AKI captured by an open (surgical) kidney biopsy performed at the time of clinically indicated laparotomy.
    Intervention: Procedure: Kidney Biopsy
  • Chronic Kidney Diseases Cohort
    High priority populations include CKD in the setting of diabetes (diabetic kidney disease, DKD) and hypertension-associated CKD (H-CKD). A special population of people with long-standing type 1 diabetes (more than 25 years) who remain free of clinically-evident DKD will also be included.
    Intervention: Procedure: Kidney Biopsy
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Recruiting
Estimated Enrollment
 (submitted: April 1, 2020)
1000
Original Estimated Enrollment Same as current
Estimated Study Completion Date June 30, 2027
Estimated Primary Completion Date June 30, 2027   (Final data collection date for primary outcome measure)
Eligibility Criteria

Chronic Kidney Disease Subjects Inclusion Criteria Diabetic kidney disease (DKD)

  • Diagnosis of diabetes mellitus (type 1 or 2) established by at least one of the following criteria:

    • Hemoglobin A1C greater than or equal to 6.5%, confirmed with a repeat test within the past year
    • Fasting blood sugar greater than or equal to 126 mg/dL, confirmed with a repeat test within the past year
    • Use of glucose-lowering therapy (insulin or oral or other subcutaneous agents)
    • International Classification of Diseases (ICD) 9/10 diagnostic code for diabetes
  • Evidence of persistent kidney damage, manifest as any of the following present on at least two clinic assessments prior to enrollment and at least 3 months apart and excluding subjects with acute medical illnesses and changing kidney function:

    • Estimated glomerular filtration rate 30-59 mL/min/1.73m2
    • Estimated glomerular filtration rate greater than or equal to 60 mL/min/1.73m2 with urine albumin excretion greater than or equal to 30 mg/g creatinine (or mg/day)
    • Estimated glomerular filtration rate greater than or equal to 60 mL/min/1.73m2 with urine protein excretion greater than or equal to 150 mg/g creatinine (or mg/day)

Hypertension-associated Chronic Kidney Disease (H-CKD) Inclusion Criteria

  • Diagnosis of hypertension (HTN) established by at least one of the following criteria:

    • BP greater than 140/90 mmHg measured on three occasions over at least 1 month
    • Taking antihypertensive medication for blood pressure (BP) control
    • International Classification of Diseases (ICD) 9/10 diagnostic code for hypertension
  • Evidence of persistent kidney damage, manifested as any of the following present on at least two assessments at least 3 months apart and excluding subjects with acute medical illnesses and changing kidney function:

    • Estimated glomerular filtration rate 30-59 mL/min/1.73m2 on two assessments at least 3 months apart with albuminuria or proteinuria less than 2000 mg/g creatinine (or mg/day)
    • Estimated glomerular filtration rate greater than or equal to 60 mL/min/1.73m2 with urine albumin excretion 30-2000 mg/g creatinine (or mg/day)
    • Estimated glomerular filtration rate greater than or equal to 60 mL/min/1.73m2 with urine protein excretion 150-2000 mg/g creatinine (or mg/day)

Acute Kidney Injury Subjects Inclusion Criteria

All three of the following criteria must be met:

  • Baseline estimated glomerular filtration rate greater than 45 mL/min/1.73m2. Baseline defined by the median of the last three outpatient serum creatinine measurements from day 7 to 365 prior to enrollment.

    • If only two measurements obtained within this window, the two results will be averaged.
    • If only one measurement was obtained within this window, this result will be used
    • If baseline is missing the potential participant can be enrolled with an estimated baseline, but only if there is no past medical history of chronic kidney disease.
  • Elevated serum creatinine (greater than or equal to 1.5 times baseline as defined above).
  • And at least ONE of the following:

    • A repeat serum creatinine within 48 hours of initial serum creatinine, showing a further increase of 0.3 mg/dL
    • Positive kidney injury urine biomarker, as defined by any of the following:

      • NGAL level greater than or equal to 150 ng/mL by ELISA or clinical analyzer
      • KIM1 level greater than or equal to 2.8 ng/mL by ELISA
      • TIMP2 x IGFBP7 greater than or equal to 2.0 by NephroCheck®
    • Urine microscopy suggestive of acute tubular necrosis defined as a urine microscopy score of greater than or equal to 2.

      • greater than or equal to 1 Renal Tubular Epithelial cells (RTE) per high powered field (HPF) AND greater than or equal to 1 granular cast/ low powered field (LPF); or
      • greater than or equal to 5 Renal Tubular Epithelial cells (RTE) per high powered field (HPF); or
      • greater than or equal to 5 granular cast/ low powered field (LPF)

General Exclusion Criteria:

  • Under 18 years of age
  • Body Mass Index (BMI) greater than 40 kg/m2
  • Allergy to iodinated contrast (any reaction)
  • Pregnancy
  • Malignancy - Receiving active chemotherapy or radiation to treat malignancy (except for nephrectomy tissue for reference and feasibility studies)
  • Transplant recipient (includes solid transplant and bone marrow)
  • Additional vulnerable individuals (incarcerated, institutionalized, or otherwise unable to participate in the study)
  • Inability to provide informed consent
  • Clinical diagnosis of kidney disease from an autoimmune disease, dysproteinemia, viral disease or glomerular disease other than DKD or H-CKD
  • Unwilling to receive blood transfusion (if needed)
Sex/Gender
Sexes Eligible for Study: All
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts
Contact: Ashveena Dighe, MS, MPH 206-744-4029 ashveena@nephrology.washington.edu
Contact: Kristina Blank, MPH 206-897-1957 blankk@uw.edu
Listed Location Countries United States
Removed Location Countries  
 
Administrative Information
NCT Number NCT04334707
Other Study ID Numbers SITE00000750
U2CDK114886 ( U.S. NIH Grant/Contract )
UH3DK114861 ( U.S. NIH Grant/Contract )
UH3DK114866 ( U.S. NIH Grant/Contract )
UH3DK114870 ( U.S. NIH Grant/Contract )
UH3DK114908 ( U.S. NIH Grant/Contract )
UH3DK114915 ( U.S. NIH Grant/Contract )
UH3DK114926 ( U.S. NIH Grant/Contract )
UH3DK114907 ( U.S. NIH Grant/Contract )
UH3DK114920 ( U.S. NIH Grant/Contract )
UH3DK114923 ( U.S. NIH Grant/Contract )
UH3DK114933 ( U.S. NIH Grant/Contract )
UH3DK114937 ( U.S. NIH Grant/Contract )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement Not Provided
Current Responsible Party Jonathan Himmelfarb, University of Washington
Original Responsible Party Same as current
Current Study Sponsor University of Washington
Original Study Sponsor Same as current
Collaborators
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  • University of Michigan
  • Icahn School of Medicine at Mount Sinai
  • Brigham and Women's Hospital
  • Broad Institute
  • The Cleveland Clinic
  • Columbia University
  • European Molecular Biology Laboratory
  • Indiana University
  • Johns Hopkins University
  • Joslin Diabetes Center
  • Pacific Northwest National Laboratory
  • Princeton University
  • Stanford University
  • Ohio State University
  • University of California, San Diego
  • University of California, San Francisco
  • University of Pittsburgh
  • The University of Texas Health Science Center at San Antonio
  • University of Texas
  • Washington University School of Medicine
  • Yale University
Investigators
Principal Investigator: Jonathan Himmelfarb, MD University of Washington
PRS Account University of Washington
Verification Date May 2022